Global Obesity Management 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12245670

Publication Date:

December 23, 2024

Pages:

133

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Obesity Management market size was valued at US$ 5415 million in 2023. With growing demand in downstream market, the Obesity Management is forecast to a readjusted size of US$ 7589.4 million by 2030 with a CAGR of 4.9% during review period.
The research report highlights the growth potential of the global Obesity Management market. Obesity Management are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Obesity Management. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Obesity Management market.
Lifestyle diseases such as diabetes and other chronic ailments are the main cause of obesity around the world. Improved healthcare and medical facilities have led to an increase in the life expectancy of people, which is the primary reason for the large geriatric population seen in the developed world. Geriatric people are far more prone to conceal sarcopenia i.e. a noticeable rise in body fat with simultaneous loss of muscle mass and functional capability.
According to public information, in 2022, there were about 1.2 billion obesity cases worldwide, among them, the number of obesity cases in China reached 230 million. Wellness & Health Research Center, the global sports economy was valued at 750 billion in 2022, 92% of global spending on physical activity occurs in Asia Pacific, North America and Europe. And China and the United States accounted for 44% of total sports spending.
Key Features:
The report on Obesity Management market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Obesity Management market. It may include historical data, market segmentation by Type (e.g., Drug, Surgery), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Obesity Management market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Obesity Management market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Obesity Management industry. This include advancements in Obesity Management technology, Obesity Management new entrants, Obesity Management new investment, and other innovations that are shaping the future of Obesity Management.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Obesity Management market. It includes factors influencing customer ' purchasing decisions, preferences for Obesity Management product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Obesity Management market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Obesity Management market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Obesity Management market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Obesity Management industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Obesity Management market.
麻豆原创 Segmentation:
Obesity Management market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Drug
Surgery
Segmentation by application
Hospitals
Speciality Clinics
Ambulatory Surgical Centres
Retail Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Allurion Technologies
Arena Pharmaceuticals
Beijing Noble Laser Technology
Eisai
GlaxoSmithKline
Johnson & Johnson
Medtronic
Nalpropion Pharmaceuticals
Novo Nordisk
Obalon Therapeutics
Orexigen Therapeutics
ReShape Lifesciences
Roche
VIVUS

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Obesity Management 麻豆原创 Size 2019-2030
2.1.2 Obesity Management 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Obesity Management Segment by Type
2.2.1 Drug
2.2.2 Surgery
2.3 Obesity Management 麻豆原创 Size by Type
2.3.1 Obesity Management 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Obesity Management 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Obesity Management Segment by Application
2.4.1 Hospitals
2.4.2 Speciality Clinics
2.4.3 Ambulatory Surgical Centres
2.4.4 Retail Pharmacies
2.5 Obesity Management 麻豆原创 Size by Application
2.5.1 Obesity Management 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Obesity Management 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Obesity Management 麻豆原创 Size by Player
3.1 Obesity Management 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Obesity Management Revenue by Players (2019-2024)
3.1.2 Global Obesity Management Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Obesity Management Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Obesity Management by Regions
4.1 Obesity Management 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Obesity Management 麻豆原创 Size Growth (2019-2024)
4.3 APAC Obesity Management 麻豆原创 Size Growth (2019-2024)
4.4 Europe Obesity Management 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Obesity Management 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Obesity Management 麻豆原创 Size by Country (2019-2024)
5.2 Americas Obesity Management 麻豆原创 Size by Type (2019-2024)
5.3 Americas Obesity Management 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Obesity Management 麻豆原创 Size by Region (2019-2024)
6.2 APAC Obesity Management 麻豆原创 Size by Type (2019-2024)
6.3 APAC Obesity Management 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Obesity Management by Country (2019-2024)
7.2 Europe Obesity Management 麻豆原创 Size by Type (2019-2024)
7.3 Europe Obesity Management 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Obesity Management by Region (2019-2024)
8.2 Middle East & Africa Obesity Management 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Obesity Management 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Obesity Management 麻豆原创 Forecast
10.1 Global Obesity Management Forecast by Regions (2025-2030)
10.1.1 Global Obesity Management Forecast by Regions (2025-2030)
10.1.2 Americas Obesity Management Forecast
10.1.3 APAC Obesity Management Forecast
10.1.4 Europe Obesity Management Forecast
10.1.5 Middle East & Africa Obesity Management Forecast
10.2 Americas Obesity Management Forecast by Country (2025-2030)
10.2.1 United States Obesity Management 麻豆原创 Forecast
10.2.2 Canada Obesity Management 麻豆原创 Forecast
10.2.3 Mexico Obesity Management 麻豆原创 Forecast
10.2.4 Brazil Obesity Management 麻豆原创 Forecast
10.3 APAC Obesity Management Forecast by Region (2025-2030)
10.3.1 China Obesity Management 麻豆原创 Forecast
10.3.2 Japan Obesity Management 麻豆原创 Forecast
10.3.3 Korea Obesity Management 麻豆原创 Forecast
10.3.4 Southeast Asia Obesity Management 麻豆原创 Forecast
10.3.5 India Obesity Management 麻豆原创 Forecast
10.3.6 Australia Obesity Management 麻豆原创 Forecast
10.4 Europe Obesity Management Forecast by Country (2025-2030)
10.4.1 Germany Obesity Management 麻豆原创 Forecast
10.4.2 France Obesity Management 麻豆原创 Forecast
10.4.3 UK Obesity Management 麻豆原创 Forecast
10.4.4 Italy Obesity Management 麻豆原创 Forecast
10.4.5 Russia Obesity Management 麻豆原创 Forecast
10.5 Middle East & Africa Obesity Management Forecast by Region (2025-2030)
10.5.1 Egypt Obesity Management 麻豆原创 Forecast
10.5.2 South Africa Obesity Management 麻豆原创 Forecast
10.5.3 Israel Obesity Management 麻豆原创 Forecast
10.5.4 Turkey Obesity Management 麻豆原创 Forecast
10.5.5 GCC Countries Obesity Management 麻豆原创 Forecast
10.6 Global Obesity Management Forecast by Type (2025-2030)
10.7 Global Obesity Management Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Allergan
11.1.1 Allergan Company Information
11.1.2 Allergan Obesity Management Product Offered
11.1.3 Allergan Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Allergan Main Business Overview
11.1.5 Allergan Latest Developments
11.2 Allurion Technologies
11.2.1 Allurion Technologies Company Information
11.2.2 Allurion Technologies Obesity Management Product Offered
11.2.3 Allurion Technologies Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Allurion Technologies Main Business Overview
11.2.5 Allurion Technologies Latest Developments
11.3 Arena Pharmaceuticals
11.3.1 Arena Pharmaceuticals Company Information
11.3.2 Arena Pharmaceuticals Obesity Management Product Offered
11.3.3 Arena Pharmaceuticals Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Arena Pharmaceuticals Main Business Overview
11.3.5 Arena Pharmaceuticals Latest Developments
11.4 Beijing Noble Laser Technology
11.4.1 Beijing Noble Laser Technology Company Information
11.4.2 Beijing Noble Laser Technology Obesity Management Product Offered
11.4.3 Beijing Noble Laser Technology Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Beijing Noble Laser Technology Main Business Overview
11.4.5 Beijing Noble Laser Technology Latest Developments
11.5 Eisai
11.5.1 Eisai Company Information
11.5.2 Eisai Obesity Management Product Offered
11.5.3 Eisai Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Eisai Main Business Overview
11.5.5 Eisai Latest Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Information
11.6.2 GlaxoSmithKline Obesity Management Product Offered
11.6.3 GlaxoSmithKline Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 GlaxoSmithKline Main Business Overview
11.6.5 GlaxoSmithKline Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Obesity Management Product Offered
11.7.3 Johnson & Johnson Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Medtronic
11.8.1 Medtronic Company Information
11.8.2 Medtronic Obesity Management Product Offered
11.8.3 Medtronic Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Medtronic Main Business Overview
11.8.5 Medtronic Latest Developments
11.9 Nalpropion Pharmaceuticals
11.9.1 Nalpropion Pharmaceuticals Company Information
11.9.2 Nalpropion Pharmaceuticals Obesity Management Product Offered
11.9.3 Nalpropion Pharmaceuticals Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Nalpropion Pharmaceuticals Main Business Overview
11.9.5 Nalpropion Pharmaceuticals Latest Developments
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Information
11.10.2 Novo Nordisk Obesity Management Product Offered
11.10.3 Novo Nordisk Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Novo Nordisk Main Business Overview
11.10.5 Novo Nordisk Latest Developments
11.11 Obalon Therapeutics
11.11.1 Obalon Therapeutics Company Information
11.11.2 Obalon Therapeutics Obesity Management Product Offered
11.11.3 Obalon Therapeutics Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Obalon Therapeutics Main Business Overview
11.11.5 Obalon Therapeutics Latest Developments
11.12 Orexigen Therapeutics
11.12.1 Orexigen Therapeutics Company Information
11.12.2 Orexigen Therapeutics Obesity Management Product Offered
11.12.3 Orexigen Therapeutics Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Orexigen Therapeutics Main Business Overview
11.12.5 Orexigen Therapeutics Latest Developments
11.13 ReShape Lifesciences
11.13.1 ReShape Lifesciences Company Information
11.13.2 ReShape Lifesciences Obesity Management Product Offered
11.13.3 ReShape Lifesciences Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 ReShape Lifesciences Main Business Overview
11.13.5 ReShape Lifesciences Latest Developments
11.14 Roche
11.14.1 Roche Company Information
11.14.2 Roche Obesity Management Product Offered
11.14.3 Roche Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Roche Main Business Overview
11.14.5 Roche Latest Developments
11.15 VIVUS
11.15.1 VIVUS Company Information
11.15.2 VIVUS Obesity Management Product Offered
11.15.3 VIVUS Obesity Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 VIVUS Main Business Overview
11.15.5 VIVUS Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.